G. Balasubramaniam

SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore.